NOVARTIS

MSN Labs wins US Appeals Court case, potentially allowing early launch of Entresto generic, challenging Novartis' projected monopoly until mid-2025.

iBox, developed by Prof. Alexandre Loupy, predicts kidney graft fate up to 10 years post-transplant. Validated in 12 centers and 3 trials, it received FDA approval in 2022, supported by AST, TTC, and major pharma. iBox optimizes treatment, reduces costs, and may revolutionize predictive medicine beyond kidney transplants.

Novartis fails to secure injunction against generic heart failure medication, with Federal Circuit backing Delaware judge's view that generic drug's ingredient is not 'amorphous'.

The precision medicine market is projected to grow by USD 66.2 billion from 2024-2028, driven by the rising prevalence of chronic diseases and the increasing use of AI and ML. However, data privacy and security issues pose challenges. Key players include AbbVie Inc., Amgen Inc., AstraZeneca Plc, and others.

The generic pharmaceuticals market was valued at USD 424.98 billion in 2024 and is projected to reach USD 874.63 billion by 2033, driven by cost-effective medications, rising chronic disease prevalence, government support, and advancements in manufacturing technologies.

AI Proteins, using computational de novo protein design, announced a collaboration with Bristol Myers Squibb to discover and develop novel miniprotein-based therapeutics, potentially worth up to $400M plus royalties. These miniproteins, designed with drug-like properties from the start, aim to offer advantages over traditional antibody therapies.

Refoxy Pharma secures $9.58 million to develop IPF drug RP-01 targeting FOXO3. Boehringer Ingelheim plans NDA submission for nerandomilast. Insilico's ISM001-055 and Endeavor's ENV-101 show disease improvement. Vicore's buloxibutid and BMS' BMS-986278 also chart progress. Pliant's bexotegrast mitigates chronic cough in IPF. IPOs and partnerships fuel IPF therapeutic field.

The Nano Biotechnology Market is projected to grow from USD 5.65 billion in 2023 to USD 12.99 billion by 2032, driven by advancements in diagnostics, therapeutics, and public health innovations.

The Nano Biotechnology Market was valued at USD 5.65 billion in 2023 and is projected to reach USD 12.99 billion by 2032, growing at a CAGR of 9.71%. The market is driven by the increasing use of nanomaterials in pharmaceuticals, medical devices, and diagnostics, enhancing efficacy and precision. Key players include Ablynx, Nami Therapeutics, and Celgene Corporation. North America leads the market, with strong investments in R&D and advanced healthcare infrastructure.